Approval · Notice of Compliance 11522 · 2010
LOVASTATIN: Notice of Compliance 11522
Issued June 16, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11522
- Date
- June 16, 2010
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Lipid metabolism regulator
- Canadian reference product
- MEVACOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LOVASTATIN | 02353229 | Cancelled Post Market |
| LOVASTATIN | 02353237 | Cancelled Post Market |
Medicinal ingredients
- LOVASTATIN 20 MG per TAB
- LOVASTATIN 40 MG per TAB